SCHEDULE: FMR LLC Discloses 6.6% Stake in Soleno Therapeutics

FMR LLC and Abigail P. Johnson have reported a passive 6.6% beneficial ownership stake in Soleno Therapeutics Inc. common stock.

Summary

• FMR LLC and Abigail P. Johnson jointly reported beneficial ownership of 3,337,857.92 shares of Soleno Therapeutics Inc. common stock.
• This represents 6.6% of the total outstanding common stock of Soleno Therapeutics Inc.
• The shares are held in the ordinary course of business and were not acquired or held for the purpose of changing or influencing control of the issuer.
• FMR LLC holds sole voting power over 3,336,788.00 shares and sole dispositive power over 3,337,857.92 shares.
• Abigail P. Johnson holds sole dispositive power over 3,337,857.92 shares.
• Fidelity Management & Research Company LLC, a subsidiary of FMR LLC, is identified as an entity beneficially owning 5% or greater of the outstanding shares.
• Other relevant entities under FMR LLC include FIAM LLC, Fidelity Institutional Asset Management Trust Company, Fidelity Management Trust Company, and Strategic Advisers LLC.

Sentiment

Score: 5

Explanation: The filing is a neutral, factual report of beneficial ownership by a large institutional investor, indicating a passive stake without any explicit positive or negative implications for the company's operations or future.

Positives

• A major institutional investor, FMR LLC, maintains a significant passive stake, indicating continued investment interest in Soleno Therapeutics Inc.

Future Outlook

The filing is a beneficial ownership report and does not contain forward-looking statements or guidance regarding Soleno Therapeutics Inc.'s future operations or financial performance.

Management Comments

• The filing includes a certification that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Industry Context

This filing is a routine disclosure of a passive institutional ownership stake, common for large asset managers like FMR LLC. It does not provide specific insights into Soleno Therapeutics Inc.'s industry position or competitive landscape.

Stakeholder Impact

• The disclosure of a significant passive stake by a major institutional investor like FMR LLC may provide a level of investor confidence for existing shareholders.

Next Steps

• The filing does not specify any future actions, events, or milestones for Soleno Therapeutics Inc. or the reporting persons beyond the routine nature of their passive investment.

Key Dates

Keywords

Soleno Therapeutics, FMR LLC, Abigail P. Johnson, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Passive Investment